Nothing Special   »   [go: up one dir, main page]

CY1110522T1 - Τυπος και διαδiκασια αμεσης συμπιεσης - Google Patents

Τυπος και διαδiκασια αμεσης συμπιεσης

Info

Publication number
CY1110522T1
CY1110522T1 CY20091101062T CY091101062T CY1110522T1 CY 1110522 T1 CY1110522 T1 CY 1110522T1 CY 20091101062 T CY20091101062 T CY 20091101062T CY 091101062 T CY091101062 T CY 091101062T CY 1110522 T1 CY1110522 T1 CY 1110522T1
Authority
CY
Cyprus
Prior art keywords
dpp
tablets
direct compression
drug
acceptable
Prior art date
Application number
CY20091101062T
Other languages
English (en)
Inventor
James Kowalski
Lakshman Jayanth Parthiban
Arun P Patel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34798877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110522(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1110522T1 publication Critical patent/CY1110522T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/26—Web or sheet containing structurally defined element or component, the element or component having a specified physical dimension
    • Y10T428/268—Monolayer with structurally defined element

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Ο αναστολέας διπεπτιδυλοπεπτιδάσης IV (στο παρόν αναφέρεται ως DPP -IV) που μπορεί να είναι καθαρός σε ποσοστό 98.5 - 100 % είναι ένα φάρμακο υψηλής δοσολογίας το οποίο μπορεί να συμπιεστεί άμεσα με συγκεκριμένα έκδοχα σε υπό πώληση μορφές δοσολογίας, όπως είναι οι ταμπλέτες και οι κάψουλες που έχουν την επιθυμητή σκληρότητα, ικανότητα θρυμματισμού και αποδεκτά χαρακτηριστικά διάλυσης. To DPP -IV δεν είναι εγγενώς συμπιέσιμο και ως εκ τούτου παρουσιάζει προβλήματα στον σχηματισμό του. Τα έκδοχα που χρησιμοποιούνται στον σχηματισμό ενισχύουν τη ροή και τις ιδιότητες συμπύκνωσης του φαρμάκου και του μείγματος δημιουργίας ταμπλετών. Η βέλτιστη ροή συμβάλλει στο ομοιόμορφο γέμισμα φιλιέρας και στον έλεγχο του βάρους. Το συνδετικό υλικό που χρησιμοποιείται διασφαλίζει επαρκείς ιδιότητες συνοχής που επιτρέπουν στο DPP -IV να συμπιέζεται, ακολουθώντας τη μέθοδο της άμεσης συμπίεσης. Οι ταμπλέτες που παράγονται παρέχουν ένα αποδεκτό προφίλ διάλυσης in vitro.
CY20091101062T 2004-01-20 2009-10-14 Τυπος και διαδiκασια αμεσης συμπιεσης CY1110522T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53770604P 2004-01-20 2004-01-20
US60427404P 2004-08-25 2004-08-25
EP05700976A EP1715893B8 (en) 2004-01-20 2005-01-17 Direct compression formulation and process

Publications (1)

Publication Number Publication Date
CY1110522T1 true CY1110522T1 (el) 2015-04-29

Family

ID=34798877

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20091101062T CY1110522T1 (el) 2004-01-20 2009-10-14 Τυπος και διαδiκασια αμεσης συμπιεσης
CY20181100840T CY1120575T1 (el) 2004-01-20 2018-08-10 Τυπος και διαδικασια αμεσης συμπιεσης
CY20211101034T CY1124770T1 (el) 2004-01-20 2021-11-29 Τυποποιηση και διαδικασια αμεσης συμπιεσης

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20181100840T CY1120575T1 (el) 2004-01-20 2018-08-10 Τυπος και διαδικασια αμεσης συμπιεσης
CY20211101034T CY1124770T1 (el) 2004-01-20 2021-11-29 Τυποποιηση και διαδικασια αμεσης συμπιεσης

Country Status (32)

Country Link
US (4) US20080038341A1 (el)
EP (5) EP3738585B1 (el)
JP (2) JP5122144B2 (el)
KR (1) KR101259645B1 (el)
AR (1) AR049000A1 (el)
AU (1) AU2005205055B2 (el)
BR (3) BR122018073405B1 (el)
CA (1) CA2552569C (el)
CY (3) CY1110522T1 (el)
DE (1) DE602005015421D1 (el)
DK (3) DK1715893T3 (el)
EC (3) ECSP066707A (el)
ES (4) ES2684325T5 (el)
HK (2) HK1221663A1 (el)
HR (2) HRP20211766T1 (el)
HU (2) HUE056586T2 (el)
IL (1) IL176831A0 (el)
LT (2) LT3023095T (el)
MA (1) MA28305A1 (el)
MX (1) MXPA06008265A (el)
MY (1) MY138450A (el)
NO (2) NO345116B1 (el)
NZ (2) NZ548351A (el)
PE (1) PE20050686A1 (el)
PH (1) PH12019501331A1 (el)
PL (4) PL3023095T3 (el)
PT (4) PT3366283T (el)
RS (2) RS62595B1 (el)
RU (1) RU2766487C2 (el)
SI (3) SI1715893T1 (el)
TW (1) TWI374760B (el)
WO (1) WO2005067976A2 (el)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3023095T3 (pl) 2004-01-20 2018-10-31 Novartis Ag Formulacja do kompresji bezpośredniej i sposób
CA2554493C (en) 2004-02-05 2012-06-26 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
WO2006096194A2 (en) * 2004-06-17 2006-09-14 Merz Pharma Gmbh & Co. Kgaa Drinkable immediate release tablet made with direct compression of memantine or neramexane
GT200600008A (es) * 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
JP2008024592A (ja) * 2005-01-28 2008-02-07 Taisho Pharmaceut Co Ltd シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
AU2006278039B2 (en) * 2005-08-11 2010-10-21 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a DPP-lV inhibitor
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
PT1976522E (pt) 2005-12-30 2013-09-09 Krka Tovarna Zdravil D D Novo Mesto Composição farmacêutica contendo montelucaste
EP2036545A1 (en) 2006-01-05 2009-03-18 Teva Pharmaceutical Industries Ltd. Aripiprazole tablets
AU2007224066B2 (en) * 2006-03-08 2011-10-27 Kyorin Pharmaceutical Co., Ltd. Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
KR101486091B1 (ko) 2007-02-01 2015-01-23 다케다 야쿠힌 고교 가부시키가이샤 알로그립틴 및 피오글리타존을 포함하는 고형 제제
AR065096A1 (es) * 2007-02-01 2009-05-13 Takeda Pharmaceutical Preparacion solida
US20100016322A1 (en) * 2007-02-28 2010-01-21 Nagesh Nagaraju Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
EP2120885A2 (en) 2007-03-13 2009-11-25 Takeda Pharmaceutical Company Limited Solid preparation comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile
ATE550319T1 (de) 2007-03-22 2012-04-15 Kyorin Seiyaku Kk Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CA2732984A1 (en) 2008-08-07 2010-02-11 Kyorin Pharmaceutical Co., Ltd. Process for production of bicyclo[2.2.2]octylamine derivative
US20110152342A1 (en) * 2008-08-14 2011-06-23 Hiroshi Uchida Stabilized pharmaceutical composition
ES2764251T3 (es) 2008-08-15 2020-06-02 Boehringer Ingelheim Int Inhibidores de DPP-4 para uso en el tratamiento de curación de heridas en pacientes diabéticos
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
RS60438B1 (sr) 2009-02-13 2020-07-31 Boehringer Ingelheim Int Farmaceutska kompozicija koja sadrži sglt2 inhibitor, dpp-iv inhibitor i opciono drugo antidijabetičko sredstvo i njihove upotrebe
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
JP2012517977A (ja) 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
EP2412370A4 (en) 2009-03-27 2013-05-22 Kyorin Seiyaku Kk MATRIX-LIKE EXTENDED RELEASE PREPARATION CONTAINING A BASIC ADDITIVE
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
US9572806B2 (en) * 2009-12-18 2017-02-21 Mitsubishi Tanabe Pharma Corporation Elution-stabilized preparation
EP2633857B1 (en) 2009-12-23 2015-08-12 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor and acetylsalicylic acid
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
CN107961377B (zh) 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
ES2953123T3 (es) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Terapia para la diabetes
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
ES2421956B1 (es) 2012-03-02 2014-09-29 Moehs Ibérica S.L. Nueva forma cristalina de sulfato de sitagliptina
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
KR102145641B1 (ko) 2012-06-05 2020-08-18 다케다 야쿠힌 고교 가부시키가이샤 고형 제제
JP6283316B2 (ja) * 2012-10-26 2018-02-21 株式会社三和化学研究所 アナグリプチン含有固形製剤
EP2769712A1 (en) 2013-02-21 2014-08-27 Siegfried International AG Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE041709T2 (hu) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
CN105377266A (zh) 2013-04-18 2016-03-02 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
TR201402685A1 (tr) 2014-03-06 2015-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vildagliptinin farmasotik formulasyonları.
EA201691793A1 (ru) * 2014-03-06 2016-12-30 Сановель Илач Санайи Ве Тиджарет А.Ш. Способ получения состава на основе вилдаглиптина в атмосфере инертного газа
PL3512505T3 (pl) 2016-09-16 2023-08-07 Galenicum Health S.L.U. Farmaceutyczne kompozycje wildagliptyny
GR1009406B (el) 2017-10-03 2018-11-26 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μεθοδος για την παρασκευη αυτου
KR102622198B1 (ko) 2018-03-30 2024-01-09 한미약품 주식회사 빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법
GR1009644B (el) 2018-09-25 2019-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου
BE1026818B1 (fr) * 2018-11-30 2020-06-30 Hedelab Sa Procede de fabrication d'une serie de n preparations pour complements alimentaires
KR102693304B1 (ko) 2019-04-16 2024-08-08 한미약품 주식회사 빌다글립틴 염산염 함유 복합 제제의 안정성 개선을 위한 포장재
JP7461735B2 (ja) * 2019-12-02 2024-04-04 日本ジェネリック株式会社 ビルダグリプチン含有錠剤
CN113018270A (zh) * 2019-12-24 2021-06-25 四川科瑞德制药股份有限公司 一种高稳定的盐酸米那普仑制剂及其制备方法
WO2024033460A1 (en) * 2022-08-12 2024-02-15 F. Hoffmann-La Roche Ag Use of co-processed excipients in continuous manufacturing of solid dosage forms

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3131402A1 (de) * 1981-08-07 1983-02-24 Kilian & Co GmbH, 5000 Köln Verfahren und tablettenpresse zum aufeinanderfolgenden herstellen einer vielzahl von tabletten mit gleichem gewicht
US4894236A (en) * 1988-01-12 1990-01-16 Choong-Gook Jang Direct compression tablet binders for acetaminophen
DE3833448A1 (de) * 1988-10-01 1990-04-12 Hoechst Ag Verfahren zur gewinnung von ibuprofen fuer die direkttablettierung
MX9206628A (es) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma Ester de prolinaboronato y metodo para su preparacion.
JP3784084B2 (ja) * 1993-10-21 2006-06-07 武田薬品工業株式会社 医薬用錠剤
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
JP3534130B2 (ja) * 1994-03-01 2004-06-07 旭化成ケミカルズ株式会社 医薬品組成物
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
WO1998018763A1 (fr) 1996-10-25 1998-05-07 Tanabe Seiyaku Co., Ltd. Derives de tetrahydroisoquinoline
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DE69839279T2 (de) 1997-11-18 2009-05-28 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Neue physiologisch aktive substanz sulphostin, herstellung und verwendung derselben
CA2319195A1 (en) 1998-02-02 1999-08-05 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
AU3034299A (en) 1998-03-09 1999-09-27 Fondatech Benelux N.V. Serine peptidase modulators
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
US6556033B1 (en) 1998-07-10 2003-04-29 Nhk Spring Co., Ltd. Electroconductive contact unit assembly
US6088938A (en) 1998-07-17 2000-07-18 Logan; John Duncan Implement adapter for an excavation tool assembly
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
AU1916401A (en) 1999-11-12 2001-06-06 Guilford Pharmaceuticals Inc. Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
MXPA02005326A (es) * 1999-11-30 2003-02-12 Dainippon Pharmaceutical Co Preparacion solida.
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
DK1743655T3 (da) * 2000-01-21 2014-08-18 Novartis Ag Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
JP2003520849A (ja) 2000-01-24 2003-07-08 ノボ ノルディスク アクティーゼルスカブ 酵素ｄｐｐ−ｉｖの阻害剤であるｎ−置換２−シアノピロールおよび−ピロリン
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
CA2400226C (en) 2000-03-31 2007-01-02 Probiodrug Ag Method for the improvement of islet signaling in diabetes mellitus and for its prevention
US6482844B1 (en) 2000-04-07 2002-11-19 Neurogen Corporation 1-benzylimidazole derivatives
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
HUP0301622A3 (en) 2000-07-04 2006-05-29 Novo Nordisk As Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them
PT1308439E (pt) 2000-08-10 2008-12-12 Mitsubishi Tanabe Pharma Corp Derivados de prolina e sua utilização como fármacos
AU2001294197C1 (en) 2000-10-06 2005-05-19 Tanabe Seiyaku Co., Ltd. Aliphatic nitrogenous five-membered ring compounds
US7510728B2 (en) * 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
WO2002053548A1 (en) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Benzothiazepine derivatives
US20040180925A1 (en) 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
CZ20032321A3 (en) 2001-02-02 2004-03-17 Takeda Chemical Industries, Ltd. Fused heterocyclic compounds
WO2002066627A1 (en) 2001-02-16 2002-08-29 Bayer Aktiengesellschaft Regulation of human dipeptidyl peptidase 8
DK1953162T3 (da) 2001-02-24 2012-09-10 Boehringer Ingelheim Pharma Xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel.
WO2002067918A1 (fr) 2001-02-27 2002-09-06 Banyu Pharmaceutical Co., Ltd. Nouveau derive de diallylmethylamine
CA2441092A1 (en) 2001-03-27 2002-10-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
FR2822826B1 (fr) * 2001-03-28 2003-05-09 Servier Lab Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0109146D0 (en) 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
EP1461334A2 (en) 2001-04-27 2004-09-29 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
FR2824825B1 (fr) * 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE523510C2 (sv) 2001-05-18 2004-04-27 Jan G Faeger Förfarande för att fastställa en varelses position och/eller orientering i förhållande till en omgivning
US20030060494A1 (en) 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
US7253172B2 (en) 2001-06-20 2007-08-07 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
AU2002344820B2 (en) 2001-06-20 2006-12-14 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
WO2003002593A2 (en) 2001-06-27 2003-01-09 Probiodrug Ag Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
US20030005443A1 (en) 2001-06-27 2003-01-02 Karin Axelsson EPG having PIP window history and sample view functionality
CN1990469A (zh) 2001-06-27 2007-07-04 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
WO2003002553A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003003250A1 (en) 2001-06-28 2003-01-09 Hywire Ltd. Range content-addressable memory
ATE388951T1 (de) 2001-07-03 2008-03-15 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
KR20040033048A (ko) 2001-09-14 2004-04-17 미츠비시 웰파마 가부시키가이샤 티아졸리딘 유도체 및 이의 약학적 용도
EP1463727A2 (en) 2001-09-19 2004-10-06 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
SE0103424D0 (sv) 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
GB0125446D0 (en) 2001-10-23 2001-12-12 Ferring Bv Novel anti-diabetic agents
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
AU2003201735B2 (en) * 2002-01-11 2008-11-13 Circ Pharma Research And Development Limited Pravastatin pharmaceutical formulations and methods of their use
WO2003057200A2 (en) 2002-01-11 2003-07-17 Novo Nordisk A/S Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
EP1476435B1 (en) 2002-02-13 2010-06-30 F. Hoffmann-La Roche Ag Novel pyridin- and pyrimidin-derivatives
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
JP2005532283A (ja) 2002-04-08 2005-10-27 トレント・ファーマシューティカルズ・リミテッド チアゾリジン−４−カルボニトリル及び類似物ならびにジペプチジル−ペプチダーゼ阻害剤としてのそれらの使用
JP2003327532A (ja) * 2002-05-10 2003-11-19 Takeda Chem Ind Ltd ペプチダーゼ阻害剤
ES2321600T3 (es) 2002-06-03 2009-06-09 Novartis Ag El uso cianopirrolidinas sustituidas para tratar hiperlipidemia.
EP1537880A4 (en) 2002-09-11 2009-07-01 Takeda Pharmaceutical PREPARATION FOR PROLONGED RELEASE
WO2004037169A2 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1553937B1 (en) 2002-10-23 2010-06-02 Bristol-Myers Squibb Company Glycinenitrile-based inhibitors of dipeptidyl peptidase iv
DE10256264A1 (de) 2002-12-03 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
WO2004071454A2 (en) 2003-02-13 2004-08-26 Guilford Pharmaceuticals Inc. Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv
AU2003207881A1 (en) 2003-02-28 2004-09-17 Aic Dipeptidyl peptidase inhibitors
US20040186046A1 (en) * 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
AR044019A1 (es) 2003-04-16 2005-08-24 Novartis Ag Proceso para la preparacion de 2-cianopirrolidinas n-sustituidas
PL3023095T3 (pl) 2004-01-20 2018-10-31 Novartis Ag Formulacja do kompresji bezpośredniej i sposób
PE20060652A1 (es) 2004-08-27 2006-08-11 Novartis Ag Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion

Also Published As

Publication number Publication date
BR122018014389B1 (pt) 2023-04-25
ES2899417T3 (es) 2022-03-11
BRPI0507007A (pt) 2007-06-05
ECSP066707A (es) 2006-10-31
CY1124770T1 (el) 2022-11-25
DE602005015421D1 (de) 2009-08-27
SI3023095T1 (sl) 2018-09-28
BR122018073405B1 (pt) 2023-04-25
MY138450A (en) 2009-06-30
HRP20181270T1 (hr) 2018-10-19
NZ548351A (en) 2009-08-28
RS57561B1 (sr) 2018-10-31
IL176831A0 (en) 2006-10-31
ES2332920T3 (es) 2010-02-15
PL3023095T3 (pl) 2018-10-31
DK3366283T3 (da) 2021-11-22
PT1715893E (pt) 2009-10-20
JP5739835B2 (ja) 2015-06-24
MXPA06008265A (es) 2006-08-31
DK1715893T3 (da) 2009-11-09
WO2005067976A3 (en) 2006-11-16
EP1715893B1 (en) 2009-07-15
ES2940341T3 (es) 2023-05-05
PE20050686A1 (es) 2005-11-08
ECSP11006707A (es) 2011-09-30
US20120294939A1 (en) 2012-11-22
NO20200892A1 (no) 2006-10-20
PT3366283T (pt) 2021-12-02
EP3023095B2 (en) 2023-11-08
PT3023095T (pt) 2018-10-19
US20080038341A1 (en) 2008-02-14
EP1715893B8 (en) 2009-12-16
EP1715893A2 (en) 2006-11-02
DK3023095T3 (en) 2018-08-20
WO2005067976A2 (en) 2005-07-28
NO20063739L (no) 2006-10-20
EP3738585B1 (en) 2022-12-14
EP3023095A1 (en) 2016-05-25
CY1120575T1 (el) 2019-07-10
HUE039902T2 (hu) 2019-02-28
KR101259645B1 (ko) 2013-04-30
AU2005205055B2 (en) 2009-06-11
PL1715893T3 (pl) 2010-03-31
EP2165703A2 (en) 2010-03-24
PL3366283T3 (pl) 2022-01-17
TW200534878A (en) 2005-11-01
ES2684325T3 (es) 2018-10-02
ECSP18089087A (es) 2018-12-31
AU2005205055A1 (en) 2005-07-28
HK1221663A1 (zh) 2017-06-09
LT3023095T (lt) 2018-09-10
PL3738585T3 (pl) 2023-04-17
RU2766487C2 (ru) 2022-03-15
CA2552569C (en) 2012-12-11
PH12019501331A1 (en) 2021-06-07
ES2684325T5 (es) 2024-06-10
KR20060129270A (ko) 2006-12-15
JP5122144B2 (ja) 2013-01-16
SI1715893T1 (sl) 2009-12-31
JP2007518760A (ja) 2007-07-12
NZ578743A (en) 2011-04-29
NO345116B1 (no) 2020-10-05
HK1255731A1 (zh) 2019-08-23
SI3366283T1 (sl) 2021-12-31
TWI374760B (en) 2012-10-21
HUE056586T2 (hu) 2022-02-28
EP3738585A1 (en) 2020-11-18
EP3366283B1 (en) 2021-09-01
MA28305A1 (fr) 2006-11-01
EP2165703A3 (en) 2012-03-28
EP3023095B1 (en) 2018-05-16
RS62595B1 (sr) 2021-12-31
RU2006130009A (ru) 2008-02-27
LT3366283T (lt) 2021-12-10
EP3366283A1 (en) 2018-08-29
JP2012176968A (ja) 2012-09-13
AR049000A1 (es) 2006-06-21
US20110236479A1 (en) 2011-09-29
CA2552569A1 (en) 2005-07-28
PT3738585T (pt) 2023-01-30
US20140205663A1 (en) 2014-07-24
HRP20211766T1 (hr) 2022-02-18

Similar Documents

Publication Publication Date Title
CY1120575T1 (el) Τυπος και διαδικασια αμεσης συμπιεσης
CY1110241T1 (el) Φαρμακευτικο σκευασμα που περιλαμβανει ενωσεις λανθανιου
WO2006135693A3 (en) Direct compression formulation of dpp-iv inhibitors and glitazones, and process
TW200716119A (en) A solid pharmaceutical dosage formulation
BRPI0707044B8 (pt) comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais
HK1067544A1 (en) Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
CO6400186A2 (es) Tabletas de acetato de ulipristal
RS57663B1 (sr) Čvrsti farmaceutski dozni oblik
BR0215193A (pt) Formulações de azitromicina diretamente compressìveis
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
UA93353C2 (ru) Производство фармацевтических композиций c быстрым высвобождением ha ochobe водонерастворимых лекарсвенных средств и фармацевтические композиции, полученные способом согласно изобретению
MXPA05013758A (es) Composiciones farmaceuticas que incluyen una antihistamina y un estimulante y uso de las mismas.
TW200509994A (en) Pharmaceutical composition exhibiting consistent drug release profile
HRP20080452T3 (en) Orally disintegrating pharmaceutical composition comprising risperidone
EA200601759A1 (ru) Композиции рамиприла
GB0001315D0 (en) Organic compounds
ZA200506992B (en) Fibrate tablet and method for the production thereof
PA8616101A1 (es) Forma de presentacion del naproxeno sodico
ATE327738T1 (de) Synergistische füllzusammensetzung
RS53359B (en) COMPOSITION OF THE FERIMANITOL OVALBUMIN TABLET
DE60324816D1 (de) Impfstoffe gegen allergien
TNSN06223A1 (en) Direct compression formulation and process
EA200700207A1 (ru) Твёрдая фармацевтическая композиция, включающая миртазапин
DK1499278T3 (da) Farmaceutisk doseringsform, som udviser umiddelbar frigivelse, og som omfatter polymorf tibolon
TW200621304A (en) Pharmaceutical composition